CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 103 enrolled
Drug / intervention
Benralizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02814643
NCT02814643Phase 3Completed
CompareCT.gov

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma.

AstraZeneca·interventional·Posted Jun 28, 2016·Updated Oct 24, 2018

In Brief

A Phase 3 clinical trial evaluating Benralizumab, Benralizumab Placebo, and 1 other intervention for Asthma. Completed, enrolled 103 participants across 24 sites.

Detailed Summary

This is a randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of a fixed dose of benralizumab administered subcutaneously (SC) on antibody responses following seasonal influenza virus vaccination

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 28, 2016
Enrollment StartJul 1, 2016
Primary CompletionJan 24, 2017
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 10.0 years ago

Interventions

Benralizumabdrug

Benralizumab SC administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).

Benralizumab Placebodrug

Placebo administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).

Seasonal influenza virus vaccinedrug

Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.